Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biogen Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BIIB
Nasdaq
2834
https://www.biogen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biogen Inc
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
- May 25th, 2022 4:07 pm
Biogen Needs a New CEO. Here Are Some Options.
- May 24th, 2022 3:13 pm
Biogen Releases 2021 Year In Review, Disclosing Progress on Climate, Health and Equity
- May 23rd, 2022 2:17 pm
Office starts to rebound as Triangle remains hot market for growth
- May 23rd, 2022 9:00 am
It's been a rocky two years for Mass. public companies. Here are some winners and losers.
- May 19th, 2022 6:16 pm
How Many Biogen Inc. (NASDAQ:BIIB) Shares Do Institutions Own?
- May 16th, 2022 6:05 pm
Biogen's Alex Cameron Discusses Biogen-MIT Biotech in Action
- May 13th, 2022 5:46 pm
The Petri Dish: Biogen seeks accelerated approval for second Alzheimer's drug
- May 12th, 2022 9:24 am
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
- May 10th, 2022 8:13 pm
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
- May 10th, 2022 6:05 pm
Biogen Partner Eisai Files for Accelerated Approval of Alzheimer’s Drug
- May 10th, 2022 3:41 pm
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
- May 10th, 2022 10:20 am
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
- May 9th, 2022 11:31 pm
Is This Growth Stock Defeated After Collapsing 22% in a Year?
- May 7th, 2022 2:30 pm
The Zacks Analyst Blog Highlights Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group
- May 6th, 2022 10:07 am
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
- May 5th, 2022 3:45 pm
Analyst Upgrades and Research Reports for Oracle, Union Pacific, Ford & Others
- May 5th, 2022 3:32 pm
Beset by challenges with its Alzheimer’s drug, Biogen pivots
- May 5th, 2022 11:38 am
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
- May 5th, 2022 11:30 am
1 Reason to Buy Biogen Now, and 1 Reason to Wait
- May 5th, 2022 10:00 am
Scroll